Evogene Ltd.

Foreign Filer Report • May 5, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

W ASillNGTON, D.C. 20549

FORM6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR lSd-16 OF TIIE SECURITIES EXCHANGE ACT OF 1934

For the month ofMay 2023

Commission File Number: 001-36187

EVOGENELm.

(Trans\ation ofRegistrant's Name into English)

13 Gad Feinstein Street, Park Rehovot, Rehovot P.O.B 4173, Ness Ziona, 7414002, Israel (Address ofprincipa\ executive offices)

Indicate by check mark whether the registrant files or will file annua\ reports under cover ofForm 20-F or Form 40-F.

Form20-F 181 Form40-F D

Indicate by check mark ifthe registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule lOl(b)(l): __

Indicate by check mark ifthe registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): __

CONTENTS

On May 4, 2023, Evogene Ltd. (the "Company") convened its Annual General Meeting of Shareholders (the "Annual Meeting"), however, it was adjourned for one week to the same day, time and place due to lack of quorum. Accordingly, the Company's Annual Meeting will be reconvened on Thursday, May 11, 2023, at 3:00 p.m. (Israel time), at the executive offices ofthe Company, 13 Gad Feinstein Street, Park Rehovot, Rehovot, Israel.

This Form 6-K is incorporated by reference into the registration statements on Form F-3 (File No. 333-253300) and on Form S-8 (File Nos. 333-193788, 333-201443, 333-203856 and 333- 259215) ofEvogene, filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

Signature

Pursuant to the requirements ofthe Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalfby the undersigned, thereunto duly authorized.

EVOGENELill. (Registrant)

ChiefFinancial Officer

Date: May 4, 2023 By: /s/ Yaron Eldad YaronEldad